A cell therapy is worthless if the cells arrive dead. Repligen is paying $1.5 billion for the freezing media that keep them alive between factory and patient.
Not the drug — the pen. Assembling the injector device is a separate industrial problem, and it has been part of the bottleneck.
Soda purchases fell 12% where SNAP restricted them. Up to 39% of the money moved to other sugary drinks the rules did not cover — which is the finding policymakers should read.
The drug was not shown to fail. It was shown not to be different enough — which in a field where a rival just succeeded is the same outcome.
12.1% weight loss from a chemically manufactured tablet. The molecule being small rather than a peptide is what would change who can get these drugs.
Spent brewer’s grain instead of refined sugar. The substrate swap is what could take algal DHA below $52 a kilogram.
A $200 million guidance cut erased $12 billion of market value. The gap between those numbers is what a growth premium costs when growth is questioned.
A 15.4-point improvement over placebo in myositis, with patients tapering off steroids. The strong signal was in a disease affecting 20,000 people with nothing approved.
Twelve weeks, 74 people, dairy-industry funding. What the trial can and cannot tell you about the low-fat advice you were given.
The high dose beat an opioid combination on pain score and left 30 percentage points more patients never needing opioid rescue at all.
Retatrutide is not approved anywhere and will not be filed until 2027. It is already being sold online as a weight-loss hack — and Lilly has flagged 14,000 websites across 100 countries.
“In every data room” but buying nothing large. A CEO a year into the job declining the move markets usually reward.